Navigation Links
Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
Date:10/3/2008

New Rochelle, NY, October 3, 2008Novel platform technologies and key advances in genomics are rapidly driving the development of molecular diagnostics, reports Genetic Engineering and Biotechnology News (GEN). The payoff for successful molecular diagnostic products can be significant as Kalorama Information predicts that this market currently exceeds $3.2 billion worldwide and will reach $5.4 billion in four years, according to an article in the October 1 issue of GEN.

"Molecular diagnostic products are based on cutting-edge research in two of the most promising biotechnologies, genomics and proteomics. These novel tests also utilize sophisticated analytical techniques such as microarrays and mass spectrometry," notes John Sterling, Editor-in-Chief of GEN. "Molecular diagnostics are particularly applicable to the early detection of cancer."

Affymetrix and Illumina have both created array-based products that enable high-speed analysis of DNA, RNA, and proteins as tools for disease research, drug development, and molecular tests. These gene-sequencing tools are being applied at an earlier stage.

Genetic tests can optimize drug therapy, and companion diagnostics are being touted as a method to better define a patient's need or predict clinical outcome from a specific drug. The FDA recently approved a HER-2 test from Invitrogen called Spot-Light that can be used to identify breast cancer patients who are candidates for treatment with Herceptin. In addition, data was recently presented showing the importance of testing for the K-ras gene to assess the clinical benefit of Erbitux for metastatic colorectal cancer.

Of all the larger integrated healthcare companies, Roche has best executed the synergies of molecular diagnostics and biopharmaceuticals and is well positioned for the future with products in oncology and infectious disease. Its genetic tests include CYP450 for drug metabolism studies and HER-2 for use with tamoxifen therapy.

Other companies covered in the GEN article include Myriad Genetics, Genomic Health, Genoptix, Luminex, Abbott Labs, Aureon, Autogenomics, Nanosphere, Navigenics, Osmetech, and Perlegen Sciences.


'/>"/>

Contact: John Sterling
jsterling@genengnews.com
914-740-2196
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Related biology technology :

1. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
2. Genetically Modified Canola Plantings Reach 90 Percent in Canada
3. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
4. A Better Tomorrow Treatment Center Inc., Forterus Inc.s Behavioral Healthcare Subsidiary, is the First in the Nation to Offer DNA-Customized Treatment for Individuals with a Genetic Predisposition for Addictive Behavior
5. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
6. Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests
7. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
8. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
9. deCODE genetics Announces Second Quarter 2008 Financial Results
10. Interleukin Genetics Announces Conference Call and Webcast to Discuss Second Quarter 2008 Business Results
11. deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia ... be hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” ... pathology adoption best practices and how Proscia improves lab economics and realizes an ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/11/2017)... ... 2017 , ... A new study published in Fertility and ... in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort study ... comparing the results from the fresh and frozen transfer cohorts, the authors of ...
(Date:10/10/2017)... ... ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled a ... new look is part of a transformation to increase awareness, appeal to new markets ... It will also expand its service offering from its signature gourmet cooking classes and ...
Breaking Biology Technology:
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/24/2017)... Controller General of Immigration from Maldives Mr. Mohamed Anwar and ... international IAIR Award for the most innovative high security ePassport and eGates  ... ... Maldives Immigration Controller General, Mr. Mohamed Anwar ... right) have received the IAIR award for the "Most innovative high security ...
Breaking Biology News(10 mins):